Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel biologic targeting retinal diseases, at the American Society of Retina Specialists meeting on July 17, 2026. TH103 is designed to treat neovascular Age-related Macular Degeneration (nAMD) by dual targeting VEGF and HSPG to improve treatment efficacy. The company is actively enrolling patients in a Phase 1b/2 trial, with initial data expected in the first half of 2027 to guide further development. This progress highlights Kalaris's commitment to advancing treatments for sight-threatening retinal conditions.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
